


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF NEW DRUG APPLICATION FOR
TQB2102 INJECTION “HER2 BISPECIFIC ADC”**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a new drug application for national Category 1 innovative drug TQB2102 Injection “HER2 Dual-epitope Bispecific ADC” independently developed by the Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), has been submitted to and accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have not received prior chemotherapy in the relapsed or metastatic setting. Previously, this indication had been granted Breakthrough Therapy Designation by the CDE.

TQB2102 is the world’s first HER2 dual-epitope bispecific antibody-drug conjugate (ADC) that achieved positive results in a Phase III clinical trial for HER2-low breast cancer. The TQB2102-III-01 study was a randomized, open-label, active-controlled, multicenter Phase III clinical study that enrolled a total of 543 patients with HER2-low breast cancer. As assessed by the Independent Data Monitoring Committee (IDMC), the study met its pre-specified primary endpoint and key secondary endpoints at the interim analysis. Compared with the investigator’s choice of chemotherapy, TQB2102 significantly reduced the risk of disease progression or death and demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). Detailed data from this study will be presented at upcoming international academic conferences.

The antibody component of TQB2102 employs an asymmetric structural design that allows it to simultaneously bind to two distinct domains of HER2, namely ECD II and ECD IV, thereby enhancing tumor cell binding and endocytosis efficiency through dual-epitope synergy. Meanwhile, it utilizes an enzyme-cleavable linker to expand its killing range against heterogeneous tumors via the “bystander effect”. TQB2102 has an optimized drug-to-antibody ratio (DAR) of approximately 5.8–6.0 and is conjugated with a topoisomerase I (Topo I) inhibitor payload, balancing enhanced anti-tumor activity with safety. This unique drug design has overcome the limitations of traditional HER2 monoclonal antibodies or single-target ADCs, potentially offering greater therapeutic advantages in HER2-low tumors.

TQB2102 is currently undergoing several Phase III clinical studies, which cover different levels of HER2 expression and multiple tumor types, including HER2-low breast cancer, neoadjuvant therapy for HER2-positive breast cancer, first-line and later-line treatment for advanced HER2-positive breast cancer, as well as later-line treatment for HER2-positive biliary tract cancer and colorectal cancer. Among these, three indications have been granted Breakthrough Therapy Designations by the CDE, further highlighting TQB2102’s broad potential for use in the treatment of HER2-expressing solid tumors.

In August 2026, the Group announced that it had entered into an exclusive license and supply agreement with Cipla Limited (“**Cipla**”) for TQB2102. The Group granted Cipla an exclusive license to develop and commercialize TQB2102 in India, South Africa, and five other emerging markets (the “**Licensed Territories**”). Cipla will be responsible for local clinical development, regulatory activities and commercialization in the Licensed Territories, while CTTQ will continue to manufacture and supply TQB2102. To date, TQB2102 has secured two regional licensing partnerships. Together, these partnerships have generated approximately US\$30 million in upfront and milestone payments for the Group, underscoring the commercial potential of the asset and the Group’s disciplined regional partnering strategy.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 16 September 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.